COPENHAGEN (Reuters) - Shares in Denmark's Novo Nordisk dropped 4.7 percent on Friday after a U.S. expert panel assessing the group's ultra long-acting insulin degludec said it will study the cardiovascular safety of the drug.
via Reuters: Health News Read More Here..
No comments:
Post a Comment